Søgeresultater - Jennifer Friedmann
- Showing 1 - 3 results of 3
-
1
-
2
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma af Rahima Jamal, Réjean Lapointe, Eftihia Cocolakis, Paméla Thébault, Shirin Kazemi, Jennifer Friedmann, Jeanne Dionne, Jean‐François Cailhier, Karl Bélanger, Jean-Pierre M. Ayoub, Huy Le, Caroline Lambert, Jida El-Hajjar, Léon C.L.T. van Kempen, Alan Spatz, Wilson H. Miller
Udgivet 2017Artigo -
3
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden af Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet, Tudor‐Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schöffski, Paolo A. Ascierto, Michele Maio, Iwona Ługowska, Lorena Lupinacci, Alexandra Léary, Jean‐Pierre Delord, Julieta Grasselli, David S.P. Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola
Udgivet 2024Artigo
Søgeredskaber:
Relaterede emner
Cancer
Internal medicine
Medicine
Immunotherapy
Ipilimumab
Oncology
Biology
Blockade
Cancer research
Carboplatin
Chemotherapy
Cisplatin
Cohort
Coronavirus disease 2019 (COVID-19)
Disease
Environmental health
Immune checkpoint
Infectious disease (medical specialty)
Intensive care medicine
Lung cancer
Medical diagnosis
Melanoma
Metastatic melanoma
Nivolumab
Paclitaxel
Paleontology
Pandemic
Pathology
Population
Receptor